Filing Flows › Interpace Biosciences (IDXG) › Q2 2026 › vs Q2 2025
Interpace Biosciences (IDXG) Q2 2026 vs Q2 2025 (year over year)
Interpace Biosciences's revenue fell $101K (-1%) from $9.2M in Q2 2025 to $9.1M in Q2 2026. Gross margin 61.9% against 57.1% (+4.8 pts).
Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%, net earnings $158K, operating cash flow $98K. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 61.9% | 57.1% | +4.8 pts |
| Operating margin | 3.5% | -5.1% | +8.6 pts |
| Net margin | 1.7% | -6.9% | +8.7 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $9.1M | $9.2M | −$101K | -1% |
| Gross profit | $5.7M | $5.3M | $377K | +7% |
| Cost of revenue | $3.5M | $4.0M | −$478K | -12% |
| Operating profit | $321K | −$468K | $789K | — |
| Operating expenses | $5.3M | $5.7M | −$412K | -7% |
| Pre-tax earnings | $222K | −$640K | $862K | — |
| Other expense, net | $99K | $172K | −$73K | -42% |
| Research & development | $149K | $173K | −$24K | -14% |
| Sales & marketing | $2.2M | $2.9M | −$703K | -24% |
| General & admin | $3.0M | $2.7M | $315K | +12% |
| Net earnings | $158K | −$640K | $798K | — |
| Income tax | $64K | $0 | $64K | — |
| Operating cash sources | $289K | −$530K | $819K | — |
| Depreciation & amortization | $127K | $101K | $26K | +26% |
| Share-based compensation | $4K | $9K | −$5K | -56% |
| Working capital & other | $191K | −$1.1M | $1.2M | — |
| Operating cash flow | $98K | $520K | −$422K | -81% |
Questions
How much did Interpace Biosciences's revenue grow year over year in Q2 2026?
Interpace Biosciences's revenue fell $101K (-1%) from $9.2M in Q2 2025 to $9.1M in Q2 2026. Gross margin 61.9% against 57.1% (+4.8 pts).